Allakos Inc. develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of gastritis and/or eosinophilic duodenitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.
Market Cap | 614.318 Million | Shares Outstanding | 85.204 Million | Avg 30-day Volume | 746.159 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -2.11 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -361.864 Million |
Price to Book Value | 1.0343 | Operating Margin | 0.0 | Enterprise Value | 30.674 Million |
Current Ratio | 12.295 | EPS Growth | -0.635 | Quick Ratio | 11.792 |
1 Yr BETA | 1.4293 | 52-week High/Low | 8.73 / 2.54 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -68.783 | Altman Z-Score | -2.1465 | Free Cash Flow to Firm | -260.517 Million |
Earnings Report | 2023-02-28 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
RADFORD HARLAN BAIRD CHIEF FINANCIAL OFFICER |
|
593,045 | 2023-01-06 | 5 |
ALEXANDER ROBERT CHIEF EXECUTIVE OFFICER |
|
1,839,319 | 2023-01-06 | 6 |
TOMASI ADAM PRESIDENT |
|
1,049,158 | 2023-01-06 | 6 |
PATERSON CRAIG A. CHIEF MEDICAL OFFICER |
|
529,902 | 2023-01-06 | 5 |
|
9,050,493 | 2022-09-21 | 2 | |
|
6,147,260 | 2022-09-21 | 2 | |
FITZGERALD MARGARET NELL GENERAL COUNSEL AND SECRETARY |
|
153,128 | 2022-09-02 | 4 |
|
0 | 2022-07-21 | 2 | |
|
99,590 | 2022-05-25 | 1 | |
|
99,590 | 2022-05-25 | 1 | |
|
99,590 | 2022-05-25 | 1 | |
ASBURY MARK CLO |
|
228,615 | 2022-02-25 | 1 |
RASMUSSEN HENRIK S MD CHIEF MEDICAL OFFICER |
|
98,550 | 2021-06-03 | 0 |
|
7,700 | 2021-05-25 | 0 | |
|
2,079,147 | 2021-03-09 | 0 | |
|
6,448,053 | 2021-03-04 | 0 | |
|
2,071,147 | 2021-03-03 | 0 | |
RIVERVEST VENTURE FUND III, L.P. RIVERVEST VENTURE FUND II (OHIO), L.P. |
|
No longer subject to file | 2021-01-04 | 0 |
ALTA PARTNERS NEXTGEN FUND I MANAGEMENT, LLC |
|
8,519,200 | 2021-01-04 | 0 |
REDMOND LEO CHIEF FINANCIAL OFFICER |
|
51,958 | 2020-12-01 | 0 |
ALTA PARTNERS NEXTGEN FUND I MANAGEMENT, LLC ALTA PARTNERS MANAGEMENT VIII, LLC |
|
10,549,114 | 2020-01-22 | 2 |
|
4,610,723 | 2018-07-23 | 0 | |
ALTA PARTNERS MANAGEMENT VIII, LLC ALTA PARTNERS NEXTGEN FUND I MANAGEMENT, LLC |
|
22,788,400 | 2018-07-23 | 0 |
|
No longer subject to file | 2018-07-23 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALEXANDER ROBERT - Director - Officer CHIEF EXECUTIVE OFFICER |
2023-01-09 18:15:10 -0500 | 2023-01-06 | A | 301,575 | a | 1,056,694 | direct | 0.2692 | 6.5949 | 9.1521 | 5 | 0.0 | 1 | |||
ALEXANDER ROBERT - Director - Officer CHIEF EXECUTIVE OFFICER |
2023-01-09 18:15:10 -0500 | 2023-01-06 | A | 462,325 | a | 462,325 | direct | |||||||||
2023-01-09 18:15:14 -0500 | 2023-01-06 | A | 102,690 | a | 372,474 | direct | 0.2692 | 6.5949 | 9.1521 | 5 | 0.0 | 1 | ||||
2023-01-09 18:15:14 -0500 | 2023-01-06 | A | 157,428 | a | 157,428 | direct | ||||||||||
2023-01-09 18:15:18 -0500 | 2023-01-06 | A | 195,997 | a | 744,734 | direct | 0.2692 | 6.5949 | 9.1521 | 5 | 0.0 | 1 | ||||
2023-01-09 18:15:18 -0500 | 2023-01-06 | A | 300,471 | a | 300,471 | direct | ||||||||||
2023-01-09 18:15:22 -0500 | 2023-01-06 | A | 126,640 | a | 398,901 | direct | 0.2692 | 6.5949 | 9.1521 | 5 | 0.0 | 1 | ||||
2023-01-09 18:15:22 -0500 | 2023-01-06 | A | 194,144 | a | 194,144 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ALLAKOS INC ALLK | 2023-02-03 22:15:03 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 21:45:03 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 21:15:03 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 20:45:06 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 20:15:04 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 19:45:03 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 19:15:04 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 18:45:03 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 18:15:03 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 17:45:03 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 17:15:04 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 16:45:04 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 16:15:03 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 15:45:03 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 15:15:03 UTC | 4.0719 | 0.4981 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 14:45:04 UTC | 3.9072 | 0.4128 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 14:15:04 UTC | 3.9072 | 0.4128 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 13:45:03 UTC | 3.9072 | 0.4128 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 13:15:03 UTC | 3.9072 | 0.4128 | 1500000 |
ALLAKOS INC ALLK | 2023-02-03 12:45:03 UTC | 3.9072 | 0.4128 | 1400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Trust for Professional Managers- Convergence Market Neutral Fund | ALLK | -736.0 shares, $-65930.88 | 2020-08-31 | N-PORT |
Trust for Professional Managers- Convergence Long/Short Equity Fund | ALLK | -407.0 shares, $-31888.45 | 2021-11-30 | N-PORT |
FundVantage Trust- Gotham Hedged Plus Fund | ALLK | -785.0 shares, $-4804.2 | 2022-09-30 | N-PORT |